Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New EHR tool aims to boost Heart-Health talks for cancer survivors

NCT ID NCT03935282

Knowledge-focused Sponsor: Wake Forest University Health Sciences Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a tool built into electronic health records that prompts doctors to discuss heart health with cancer survivors during routine visits. Researchers enrolled 645 survivors of breast, prostate, colorectal, endometrial, and lymphoma cancers across 12 clinics. The goal was to see if the tool increases conversations about heart risks, referrals to heart doctors, and healthy lifestyle changes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Automated Heart-Health Assessment (AH-HA) tool in the EPIC EHR
What this could lead to
If successful, this tool could help cancer survivors and their doctors talk more about heart health, leading to better referrals and healthier habits.
What could go wrong
This is an early-stage implementation study, not a treatment trial. The tool may not change actual health outcomes, and results may not apply to all clinics.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

645 people

The number who actually took part.

Started

Oct 2020

Finished

Nov 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * \>= 6 months post-potentially curative cancer treatment for breast, prostate, colorectal, or endometrial cancers or Hodgkin and non-Hodgkin lymphomas. Ongoing hormonal therapies such as tamoxifen, aromatase inhibitors (with or without adjuvant CDK 4/6 inhibitors such as abemaciclib), or androgen deprivation are allowed. * Scheduled for a routine cancer-related follow-up care visit within the next 30 days with a provider who received training to use AH-HA. * Able and willing to complete a follow-up assessment in one year. * Survivors must have no evidence of disease at the time of last medical visit for all cancers, except non-melanoma skin disease. * Age \>= 18 years. * Able to understand and willing to provide verbal informed consent. Exclusion Criteria: * Survivors will be excluded if they have a history of cancer recurrence for any cancer other than non-melanoma skin disease. * Prostate patients on active surveillance will be excluded. * Survivor does not speak English or Spanish. * Survivors who are currently on another interventional protocol in which cardiovascular risk factors (e.g., blood pressure, smoking, diet, physical activity) are being addressed, as per patient self-report or research staff members' knowledge at the time of consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast neoplasm are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast neoplasm cardiovascular disorder classic Hodgkin lymphoma colorectal neoplasm endometrial cancer endometrium neoplasm Health Behavior Hodgkins lymphoma neoplasm non-Hodgkin lymphoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast neoplasm Colorectal neoplasms Endometrial neoplasms Hodgkin disease Non-Hodgkin lymphoma Prostatic neoplasm

Contacts and locations

Locations

  • Baptist Memorial Hospital and Cancer Center-Memphis

    Memphis, Tennessee, 38120, United States

  • Baptist Memorial Hospital for Women

    Memphis, Tennessee, 38120, United States

  • Community Medical Center

    Scranton, Pennsylvania, 18510, United States

  • Geisinger Wyoming Valley/Henry Cancer Center

    Wilkes-Barre, Pennsylvania, 18711, United States

  • Mercy Hospital Fort Smith

    Fort Smith, Arkansas, 72903, United States

  • Mercy Hospital Oklahoma City

    Oklahoma City, Oklahoma, 73120, United States

  • Mercy Hospital Saint Louis

    St Louis, Missouri, 63141, United States

  • Mercy Hospital Springfield

    Springfield, Missouri, 65804, United States

  • Oncology Associates at Mercy Medical Center

    Cedar Rapids, Iowa, 52403, United States

  • Saint Louis Cancer and Breast Institute-Ballwin

    Ballwin, Missouri, 63011, United States

  • ThedaCare Regional Cancer Center

    Appleton, Wisconsin, 54911, United States

  • Virginia Commonwealth University/Massey Cancer Center

    Richmond, Virginia, 23298, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.